Price
CHART BY
Frequently asked questions
What is Newron's market capitalization?
The market capitalization of Newron is $328.31M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Newron's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Newron is 11.77. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Newron?
Newron's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $1.397. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Newron's stock?
Currently, 2 analysts cover Newron's stock, with a consensus target price of $18.06. Analyst ratings provide insights into the stock's expected performance.
What is Newron's revenue over the trailing twelve months?
Over the trailing twelve months, Newron reported a revenue of $65.90M.
What is the EBITDA for Newron?
Newron's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $38.95M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Newron?
Newron has a free cash flow of $27.11M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
What is the free float of Newron's shares?
The free float of Newron is 17.52M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $328.31M
- EPS (TTM)
- $1.397
- Free Float
- 17.52M
- P/E ratio (TTM)
- 11.77
- Revenue (TTM)
- $65.90M
- EBITDA (TTM)
- $38.95M
- Free Cashflow (TTM)
- $27.11M
Pricing
- 1D span
- $17.56$18.35
- 52W span
- $6.045$17.69
Analyst Ratings
The price target is $18.06 and the stock is covered by 2 analysts.
Buy
1
Hold
1
Sell
0
Information
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- IT0004147952
- Primary Ticker
- NWRN
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet